shaquille gets real about heart failure

Heart failure disproportionately affects the African American community.1 And although I don’t have heart failure, the issue hits close to home. That’s why I’m teaming up with Arbor to drive awareness about the first heart failure medication indicated for self-identified African American patients. And together, let’s learn more about managing heart failure and how it may be more affordable than ever.

African American Heart Failure Disparity

African American patients are disproportionately at risk for heart failure for a number of reasons, ranging from modifiable risk factors to vascular regulation.2

African Americans are 20 times more likely to develop HF before the age of 50 versus whites.1

Not an actual patient

Heart Failure in the African American Community

African American patients have higher rates of impaired endothelial function and less arterial elasticity than white and Chinese American patients. These factors may be related to increased oxidative stress, decreased nitric oxide availability, exaggerated vasoconstrictor response, and attenuated responsiveness to vasodilators and nitric oxide.2

Learn more about heart failure in African American patients

Not an actual patient.

Heart Failure in the African American Community

African American patients have higher rates of impaired endothelial function and less arterial elasticity than white and Chinese American patients. These factors may be related to increased oxidative stress, decreased nitric oxide availability, exaggerated vasoconstrictor response, and attenuated responsiveness to vasodilators and nitric oxide.2

Learn more about heart failure in African American patients

Prescribing BiDil® for Heart Failure

BiDil is the first medication specifically indicated to treat heart failure in African American patients.

In the African-American Heart Failure Trial (A-HeFT), a double-blind study of 1050 African American patients who had class III or class IV heart failure, BiDil was found to reduce the rate of death by 43% and risk of first hospitalization by 39% vs placebo when added to standard heart failure therapy.3

The primary endpoint was a composite of these two and functional status.


Kaplan-Meier Plot of Time to Death by Any Cause in African American Patients (A-HeFT)3


African American heart failure death and BiDil treatment reduction graph

Kaplan-Meier Plot of Time to First Hospitalization for Heart Failure in African American Patients (A-HeFT)3


African American heart failure hospitalization and BiDil treatment reduction graph Study Design

*Improvement and reduction represents full length of the follow up.

Patients taking BiDil in the A-HeFT study also reported significant improvement in their ability to function day to day compared with those on standard therapy alone.4

Not an actual patient.

Clinical Pharmacology and Pathophysiology

The combination of isosorbide dinitrate and hydralazine may serve as a nitric oxide (NO) donor,4 and hydralazine may reduce tolerance to nitrates.3

Conventional heart failure treatment addresses the neurohormonal excesses but do not impact nitric oxide. Lower levels or lower activity of nitric oxide may contribute to heart failure prevalence in African American patients.4 Medication that augments nitric oxide may be an important adjunct to optimal heart failure treatment for this population.4

Learn more about BiDil efficacy
Shaq BiDil Access Program, heart failure medication affordability

Assistance. Access. Answers.

Get effective care into the hands of those who need it the most.

Shaq BiDil Access Program, heart failure medication affordability

Assistance. Access. Answers.

Get effective care into the hands of those who need it the most.

BiDil Patient Savings Card

Eligible patients may pay as little as $0 for their first fill of BiDil (up to 90 tablets) and as little as $25 for refills 2 through 12.

Medicare/Medicaid patients not eligible.

Enroll Your Patients

Preferred Arbor E-Z Rx Pharmacies

Insured patients pay just $10 and cash patients just $50 for each monthly supply of BiDil (up to 90 tablets per month). Copay requirements apply.

Medicare/Medicaid patients not eligible.

Find Participating Pharmacies

Cash Savings & Home Delivery

Arbor Patient Direct is a free premium prescription home delivery service that may be able to help patients willing to pay cash with prescription affordability.
Call 844-289-3981 now to enroll.

Visit Arbor Patient Direct

For information about formulary coverage, visit BiDil.com.

Shaq BiDil Access Program, heart failure medication affordability

Assistance. Access. Answers.

Get effective care into the hands of those who need it the most.

BiDil Patient Savings Card

Eligible patients may pay as little as $0 for their first fill of BiDil (up to 90 tablets) and as little as $25 for refills 2 through 12.

Medicare/Medicaid patients not eligible.

Enroll Your Patients

Preferred Arbor E-Z Rx Pharmacies

Insured patients pay just $10 and cash patients just $50 for each monthly supply of BiDil (up to 90 tablets per month). Copay requirements apply.

Medicare/Medicaid patients not eligible.

Find Participating Pharmacies

Cash Savings and Home Delivery

Arbor Patient Direct is a free premium prescription home delivery service that may be able to help patients willing to pay cash with prescription affordability.

Call 844-289-3981 now to enroll.

Visit Arbor Patient Direct

For information about formulary coverage, visit BiDil.com.

Shaq Access Resource Library

Video Gallery

Heart To Heart

Dr. Ofili explains how heart failure impacts African Americans and an available treatment option.

H.E.A.R.T.

Up for a game of H.E.A.R.T.? Shoot hoops with Shaq & learn how heart failure affects African Americans.

Step Up Our Game

Shaq and Dr. Ofili map out a game plan for helping African Americans face off against heart failure.

INDICATIONS AND USAGE

BiDil is indicated for the treatment of heart failure as an adjunct to standard therapy in self-identified black patients to improve survival, to prolong time to hospitalization for heart failure, and to improve patient-reported functional status. There is little experience in patients with NYHA class IV heart failure. Most patients in the clinical trial supporting effectiveness (A-HeFT) received a loop diuretic, an angiotensin converting enzyme inhibitor or an angiotensin II receptor blocker, and a beta blocker, and many also received a cardiac glycoside or an aldosterone antagonist.

IMPORTANT SAFETY INFORMATION

BiDil is contraindicated in patients who are allergic to organic nitrates, or who take phosphodiesterase type 5 (PDE5) inhibitors, such as avanafil, sildenafil, tadalafil, or vardenafil, or soluble guanylate cyclase (sGC) stimulator (riociguat). Concomitant use can cause hypotension.

WARNINGS AND PRECAUTIONS

Hydralazine hydrochloride has been reported to cause a drug-induced systemic lupus erythematosus (SLE) syndrome. Symptoms and signs usually regress when hydralazine hydrochloride is discontinued.

Symptomatic hypotension, particularly with upright posture, may occur with even small doses of BiDil. Hypotension is most likely to occur in patients who have been volume or salt depleted; correct prior to initiation of BiDil. Hydralazine hydrochloride can cause tachycardia and hypotension potentially leading to myocardial ischemia and angina, particularly in patients with hypertrophic cardiomyopathy.

Hydralazine hydrochloride has been associated with peripheral neuritis, evidenced by paresthesia, numbness, and tingling, which may be related to an antipyridoxine effect. Pyridoxine should be added to BiDil therapy if such symptoms develop.

ADVERSE REACTIONS

Most common adverse reactions (> 5% more on BiDil than on placebo) were headache and dizziness.

The full Prescribing Information for BiDil is available here.

References 1. Bibbins-Domingo K, Pletcher MJ, Lin F, et al. Racial differences in incident heart failure among young adults. N Engl J Med. 2009;360(12):1179-1190. 2. Sharma A, Colvin-Adams M, Yancy CW. Heart failure in African Americans: disparities can be overcome. Clev Clin J Med. 2014;81(5):301-311. 3. BiDil [package insert]. Atlanta, GA: Arbor Pharmaceuticals, Inc; 2015. 4. Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;351(20):2049-2057.